Detailansicht

Wissensnetz

Person

Michael Staehler

Urologe

Name	Michael Staehler
Ort	Deutschland
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Urologe (charakteristischer Beruf)
Weitere Angaben	Oberarzt. Urologische Onkologie, LMU Klinikum München
Datensatztyp	Person
GND-Nummer	1300674326
Datensatz-ID	1300674326
Beteiligt an alle anzeigen Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial Aktuelle nuklearmedizinische Entwicklungen beim fortgeschrittenen Nierenzellkarzinom Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma The Burden of Fear of Cancer Recurrence in Genitourinary Cancers: A Prospective Study (NCT04535921) Dynamics of urinary and respiratory shedding of Severe acute respiratory syndrome virus 2 (SARS-CoV-2) RNA excludes urine as a relevant source of viral transmission 68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results Polyethylene glycol-coated collagen patch (hemopatch®) in open partial nephrectomy Listening to Music during Outpatient Cystoscopy Reduces Pain and Anxiety and Increases Satisfaction: Results from a Prospective Randomized Study Mapping Telemedicine in German Private Practice Urological Care: Implications for Transitioning beyond the COVID-19 Pandemic Does Pandemic Anxiety Affect Urology Health Care Workers? COVID-19 and financial toxicity in patients with renal cell carcinoma First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECT—correlation with microvascular density Optimized management of urolithiasis by coloured stent-stone contrast using dual-energy computed tomography (DECT) External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study Möglichst organerhaltend operieren : Behandlungsoptionen beim Nierenzellkarzinom Plasma N-Terminal Pro-Brain Natriuretic Peptide as Prognostic Marker in Fatal Cardial Decompensation with Sunitinib Malate Therapy

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Michael Staehler

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

Aktuelle nuklearmedizinische Entwicklungen beim fortgeschrittenen Nierenzellkarzinom

Robotic stereotactic body radiotherapy for localized prostate cancer: final analysis of the German HYPOSTAT trial

Evaluation of Gas 6 as a Prognostic Marker in Papillary Renal Cell Carcinoma

Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial

The Prognostic Impact of PD-L2 in Papillary Renal-Cell Carcinoma

The Burden of Fear of Cancer Recurrence in Genitourinary Cancers: A Prospective Study (NCT04535921)

Dynamics of urinary and respiratory shedding of Severe acute respiratory syndrome virus 2 (SARS-CoV-2) RNA excludes urine as a relevant source of viral transmission

68Ga-EMP-100 PET/CT—a novel ligand for visualizing c-MET expression in metastatic renal cell carcinoma—first in-human biodistribution and imaging results

Polyethylene glycol-coated collagen patch (hemopatch®) in open partial nephrectomy

Listening to Music during Outpatient Cystoscopy Reduces Pain and Anxiety and Increases Satisfaction: Results from a Prospective Randomized Study

Mapping Telemedicine in German Private Practice Urological Care: Implications for Transitioning beyond the COVID-19 Pandemic

Does Pandemic Anxiety Affect Urology Health Care Workers?

COVID-19 and financial toxicity in patients with renal cell carcinoma

First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

Papillary vs clear cell renal cell carcinoma. Differentiation and grading by iodine concentration using DECT—correlation with microvascular density

Optimized management of urolithiasis by coloured stent-stone contrast using dual-energy computed tomography (DECT)

External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma

Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer

Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study

Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional study

Möglichst organerhaltend operieren : Behandlungsoptionen beim Nierenzellkarzinom

Plasma N-Terminal Pro-Brain Natriuretic Peptide as Prognostic Marker in Fatal Cardial Decompensation with Sunitinib Malate Therapy